Moderna personalized mRNA cancer vaccine succeeds in Phase 3 trial
thedealdirector · x · 2026-08-20
Moderna and Merck announced that a personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial, marking the first late-stage win for an individualized mRNA cancer therapy. Moderna's stock surged about 90% on the news.
More from Research
- OrganicHAR at UbiComp 2026: Discovering Activities Sensors Can Actually Distinguish — mynkgoel · 2026-10-16
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16